Distribution of Prevention Resources and Impact on Sexual Health in the USA

  • Harrell W. ChessonEmail author
  • Steven D. Pinkerton
  • David R. Holtgrave


The hypothesis that reductions in sexually transmitted disease (STD) prevention resources can lead to subsequent increases in STD rates is known in the STD field as “Brown’s Law.” This aphorism is named for Dr. William Brown, the former leader of what is now the Division of STD Prevention within the Centers for Disease Control and Prevention (CDC), who warned against premature reductions in STD prevention budgets [1, 2]. “As the point of eradication is approached,” he said, “it is more often the program that is eradicated than the disease.” [2].


Sexually Transmitted Disease League Table Resource Allocation Model Prevention Resource Prevention Funding 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Chaulk CP, Zenilman J. Sexually transmitted disease control in the era of managed care: “magic bullet” or “shadow on the land”? J Public Health Manag Pract. 1997;3:61–70.PubMedGoogle Scholar
  2. 2.
    Etheridge EW. Sentinel for health: a history of the centers for disease control. Berkeley and Los Angeles, CA: University of California Press; 1992.Google Scholar
  3. 3.
    Siegel JE. Estimates of the economic burden of STDs: review of the literature with updates. In: Eng TR, Butler WT, editors. The hidden epidemic: confronting sexually transmitted diseases. Washington, DC: National Academy Press; 1997. p. 330–56.Google Scholar
  4. 4.
    Alexander LL, Cates JR, Herndon N, Ratcliffe JF, American Social Health Association. Sexually transmitted diseases in America how many cases and at what cost? Menlo Park, CA: Kaiser Family Foundation; 1998.Google Scholar
  5. 5.
    Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health. 2004;36:11–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Institute of Medicine (Committee on Prevention and Control of Sexually Transmitted Diseases). The hidden epidemic: confronting sexually transmitted diseases. Washington, DC: National Academy Press; 1997.Google Scholar
  7. 7.
    Chesson HW, Harrison P, Scotton CR, Varghese B. Does funding for HIV and sexually transmitted disease prevention matter? Evidence from panel data. Eval Rev. 2005;29:3–23.PubMedCrossRefGoogle Scholar
  8. 8.
    Linas BP, Zheng H, Losina E, Walensky RP, Freedberg KA. Assessing the impact of federal HIV prevention spending on HIV testing and awareness. Am J Public Health. 2006;96:1038–43.PubMedCrossRefGoogle Scholar
  9. 9.
    Holtgrave DR, Kates J. HIV incidence and CDC’s HIV prevention budget: an exploratory correlational analysis. Am J Prev Med. 2007;32:63–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Sansom SL, Harris NS, Sadek R, Lampe MA, Ruffo NM, Fowler MG. Toward elimination of perinatal human immunodeficiency virus transmission in the United States: effectiveness of funded prevention programs, 1999–2001. Am J Obstet Gynecol. 2007;197:S90–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Chesson H, Owusu-Edusei Jr K. Examining the impact of federally-funded syphilis elimination activities in the USA. Soc Sci Med. 2008;67:2059–62.PubMedCrossRefGoogle Scholar
  12. 12.
    Holtgrave DR. The president’s fiscal year 2007 initiative for human immunodeficiency virus counseling and testing expansion in the United States: a scenario analysis of its coverage, impact, and cost-effectiveness. J Public Health Manag Pract. 2007;13:239–43.PubMedGoogle Scholar
  13. 13.
    Holtgrave DR. Estimating the effectiveness and efficiency of US HIV prevention efforts using scenario and cost-effectiveness analysis. AIDS. 2002;16:2347–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Holtgrave DR. When “heightened” means “lessened”: the case of HIV prevention resources in the United States. J Urban Health. 2007;84:648–52.PubMedCrossRefGoogle Scholar
  15. 15.
    Holtgrave DR, Pinkerton SD, Merson M. Estimating the cost of unmet HIV-prevention needs in the United States. Am J Prev Med. 2002;23:7–12.PubMedCrossRefGoogle Scholar
  16. 16.
    Chesson HW. Estimated effectiveness and cost-effectiveness of federally funded prevention efforts on gonorrhea rates in the United States, 1971–2003, under various assumptions about the impact of prevention funding. Sex Transm Dis. 2006;33:S140–4.PubMedCrossRefGoogle Scholar
  17. 17.
    White PJ, Ward H, Cassell JA, Mercer CH, Garnett GP. Vicious and virtuous circles in the dynamics of infectious disease and the provision of health care: gonorrhea in Britain as an example. J Infect Dis. 2005;192:824–36.PubMedCrossRefGoogle Scholar
  18. 18.
    Hornberger J, Holodniy M, Robertus K, Winnike M, Gibson E, Verhulst E. A systematic review of cost-utility analyses in HIV/AIDS: Implications for public policy. Medical Decision Making. 2007;27:789–821.PubMedCrossRefGoogle Scholar
  19. 19.
    Pinkerton SD, Johnson-Masotti AP, Holtgrave DR, Farnham PG. Using cost-effectiveness league tables to compare interventions to prevent sexual transmission of HIV. AIDS. 2001;15:917–28.PubMedCrossRefGoogle Scholar
  20. 20.
    Holtgrave DR, Qualls NL, Curran JW, Valdiserri RO, Guinan ME, Parra WC. An overview of the effectiveness and efficiency of HIV prevention programs. Public Health Rep. 1995;110:134–46.PubMedGoogle Scholar
  21. 21.
    Oakley A, Fullerton D, Holland J. Behavioural interventions for HIV/AIDS prevention. AIDS. 1995;9:479–86.PubMedGoogle Scholar
  22. 22.
    Stephenson JM, Imrie J, Sutton SR. Rigorous trials of sexual behaviour interventions in STD/HIV prevention: what can we learn from them? AIDS. 2000;14 Suppl 3:S115–124.Google Scholar
  23. 23.
    Mullen PD, Ramirez G, Strouse D, Hedges LV, Sogolow E. Meta-analysis of the effects of behavioral HIV prevention interventions on the sexual risk behavior of sexually experienced adolescents in controlled studies in the United States. J Acquir Immune Defic Syndr. 2002;30 Suppl 1:S94–105.Google Scholar
  24. 24.
    Johnson WD, Hedges LV, Ramirez G, et al. HIV ­prevention research for men who have sex with men: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2002;30 Suppl 1:S118–129.Google Scholar
  25. 25.
    Semaan S, Des Jarlais DC, Sogolow E, et al. A meta-analysis of the effect of HIV prevention interventions on the sex behaviors of drug users in the United States. J Acquir Immune Defic Syndr. 2002;30 Suppl 1:S73–93.Google Scholar
  26. 26.
    Neumann MS, Johnson WD, Semaan S, et al. Review and meta-analysis of HIV prevention intervention research for heterosexual adult populations in the United States. J Acquir Immune Defic Syndr. 2002;30 Suppl 1:S106–117.Google Scholar
  27. 27.
    Semaan S, Kay L, Strouse D, et al. A profile of U.S.-based trials of behavioral and social interventions for HIV risk reduction. J Acquir Immune Defic Syndr. 2002;30 Suppl 1:S30–50.Google Scholar
  28. 28.
    Honey E, Augood C, Templeton A, et al. Cost effectiveness of screening for Chlamydia trachomatis: a review of published studies. Sex Transm Infect. 2002;78:406–12.PubMedCrossRefGoogle Scholar
  29. 29.
    Lyles CM, Kay LS, Crepaz N, et al. Best-evidence interventions: findings from a systematic review of HIV behavioral interventions for US populations at high risk, 2000–2004. Am J Public Health. 2007;97:133–43.PubMedCrossRefGoogle Scholar
  30. 30.
    Institute of Medicine (Committee on HIV prevention strategies in the United States). No time to lose: getting more from HIV prevention. Washington, DC: National Academy Press; 2000.Google Scholar
  31. 31.
    Paltiel AD, Stinnett AA. Resource allocation and the funding of HIV prevention. In: Holtgrave DR, editor. Handbook of economic evaluation of HIV prevention programs. New York: Plenum; 1998. p. 135–52.Google Scholar
  32. 32.
    Brandeau ML. Difficult choices, urgent needs: optimal investment in HIV prevention programs. In: Kaplan EH, Brookmeyer R, editors. Quantitative evaluation of HIV prevention programs. New Haven: Yale University Press; 2002. p. 97–117.Google Scholar
  33. 33.
    Kaplan EH, Pollack H. Allocating HIV prevention resources. Socioecon Plann Sci. 1998;32:257–63.CrossRefGoogle Scholar
  34. 34.
    Kahn JG. The cost-effectiveness of HIV prevention targeting: how much more bang for the buck? Am J Public Health. 1996;86:1709–12.PubMedCrossRefGoogle Scholar
  35. 35.
    Bautista-Arredondo S, Gadsden P, Harris JE, Bertozzi SM. Optimizing resource allocation for HIV/AIDS prevention programmes: an analytical framework. AIDS. 2008;22 Suppl 1:S67–74.Google Scholar
  36. 36.
    Brandeau ML, Zaric GS, de Angelis V. Improved allocation of HIV prevention resources: using information about prevention program production functions. Health Care Manag Sci. 2005;8:19–28.PubMedCrossRefGoogle Scholar
  37. 37.
    Cohen DA, Wu SY, Farley TA. Cost-effective allocation of government funds to prevent HIV infection. Health Aff (Millwood). 2005;24:915–26.CrossRefGoogle Scholar
  38. 38.
    Earnshaw SR, Hicks K, Richter A, Honeycutt A. A linear programming model for allocating HIV prevention funds with state agencies: a pilot study. Health Care Manag Sci. 2007;10:239–52.PubMedCrossRefGoogle Scholar
  39. 39.
    Lasry A, Carter MW, Zaric GS. S4HARA: System for HIV/AIDS resource allocation. Cost Eff Resour Alloc. 2008;6:7.PubMedCrossRefGoogle Scholar
  40. 40.
    Richter A, Brandeau ML, Owens DK. An analysis of optimal resource allocation for prevention of infection with human immunodeficiency virus (HIV) in injection drug users and non-users. Med Decis Making. 1999;19:167–79.PubMedCrossRefGoogle Scholar
  41. 41.
    Richter A, Hicks KA, Earnshaw SR, Honeycutt AA. Allocating HIV prevention resources: a tool for state and local decision making. Health Policy. 2008;87:342–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Pinkerton SD, Abramson PR. Model-based allocation of HIV-prevention resources. AIDS Public Policy J. 1996;11:153–5.PubMedGoogle Scholar
  43. 43.
    Bibus DP. A model for distributing HIV-prevention resources. AIDS Public Policy J. 1994;9:197–207.Google Scholar
  44. 44.
    American Social Health Association. Show me the money: state investment in STD prevention, FY2007. 2008.Google Scholar
  45. 45.
    Kates J, Penner M, Kern D, Carbaugh A, Ginsberg B, Jorstad C. The national HIV prevention inventory: the state of HIV prevention across the U.S. A report by NASTAD and the Kaiser Family Foundation. Menlo Park, CA: National Alliance of State and Territorial AIDS Directors; 2009.Google Scholar
  46. 46.
    Summers T, Alagiri P, Kates J. Federal HIV/AIDS spending. A budget chartbook: fiscal year 2002. Kaiser Family Foundation; 2003.Google Scholar
  47. 47.
    Department of Health and Human Services. Justification of estimates for appropriation committees: Centers for Disease Control and Prevention. Fiscal year 2010; 2009.Google Scholar
  48. 48.
    Division of STD Prevention, CDC. CDC history of STD funding. 2009.Google Scholar
  49. 49.
    Centers for Disease Control and Prevention. CDC’s HIV/AIDS prevention activities. 2002.Google Scholar
  50. 50.
    Douglas Jr JM. Sexually transmitted infections in young women. Congressional Briefing, 24 April 2008. 2008.Google Scholar
  51. 51.
    National Center for HIV/AIDS, viral hepatitis STD and TB prevention. NCHHSTP state profiles. 2009.Google Scholar
  52. 52.
    Colander DC. Economics. 5th ed. New York: McGraw-Hill; 2004.Google Scholar
  53. 53.
    Kaplan EH, Merson MH. Allocating HIV-prevention resources: balancing efficiency and equity. Am J Public Health. 2002;92:1905–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Centers for Disease Control and Prevention. Sexually transmitted disease surveillance, 2007. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2008.Google Scholar
  55. 55.
    Cutler JC, Arnold RC. Venereal disease control by health departments in the past: lessons for the present. Am J Public Health. 1988;78:372–6.PubMedCrossRefGoogle Scholar
  56. 56.
    Holtgrave DR, Pinkerton SD. Implications of economic evaluation for national HIV prevention policy makers. In: Kaplan EH, Brookmeyer R, editors. Quantitative evaluation of HIV prevention programs. New Haven: Yale University Press; 2002. p. 32–52.Google Scholar
  57. 57.
    Hallett TB, White PJ, Garnett GP. Appropriate evaluation of HIV prevention interventions: from experiment to full-scale implementation. Sex Transm Infect. 2007;83 Suppl 1:i55–60.Google Scholar
  58. 58.
    Walker PT, Hallett TB, White PJ, Garnett GP. Interpreting declines in HIV prevalence: impact of spatial aggregation and migration on expected declines in prevalence. Sex Transm Infect. 2008;84 Suppl 2:ii42–48.Google Scholar
  59. 59.
    Heaton LM, Komatsu R, Low-Beer D, Fowler TB, Way PO. Estimating the number of HIV infections averted: an approach and its issues. Sex Transm Infect. 2008;84 Suppl 1:i92–96.Google Scholar
  60. 60.
    U.S. House of Representatives, Committee on Oversight and Government Reform. The domestic epidemic is worse than we thought: a wake-up call for HIV prevention. Committee on Oversight and Government Reform; 2008.Google Scholar
  61. 61.
    Zaric GS, Brandeau ML. A little planning goes a long way: multilevel allocation of HIV prevention resources. Med Decis Making. 2007;27:71–81.PubMedCrossRefGoogle Scholar
  62. 62.
    The Futures Group International. Resource allocation for HIV/AIDS programs: using the goals model to relate expenditures to program goals. The Futures Group International; 2001.Google Scholar
  63. 63.
    World Bank. Optimizing the allocation of resources for HIV prevention: the allocation by cost-effectiveness (ABC) model. Guidelines. Washington, DC: World Bank; 2002.Google Scholar
  64. 64.
    Cohen DA, Farley T, Wu S. Maximizing the benefit: HIV prevention planning based on cost-effectiveness. A practical tool for community planning groups and health departments. RAND; 2004.Google Scholar
  65. 65.
    Cohen DA, Wu SY, Farley TA. Comparing the ­cost-effectiveness of HIV prevention interventions. J Acquir Immune Defic Syndr. 2004;37:1404–14.PubMedCrossRefGoogle Scholar
  66. 66.
    Lasry A, Sansom SL, Hicks KA, Uzunangelov V. Modeling the impact of HIV prevention strategies in the United States. 2009 National HIV Prevention Conference; 2009.Google Scholar
  67. 67.
    Division of STD Prevention. SOCRATES: Screening optimally for chlamydia: resource allocation, testing and evaluation software. Atlanta: Centers for Disease Control and Prevention; 2003.Google Scholar
  68. 68.
    Tao G, Gift TL, Walsh CM, Irwin KL, Kassler WJ. Optimal resource allocation for curing Chlamydia trachomatis infection among asymptomatic women at clinics operating on a fixed budget. Sex Transm Dis. 2002;29:703–9.PubMedCrossRefGoogle Scholar
  69. 69.
    Chesson H, Collins D, Koski K. STIC Figure. Sexually Transmitted Infection Costs saved. Instruction manual. Atlanta: Division of STD Prevention, Centers for Disease Control and Prevention; 2008.Google Scholar
  70. 70.
    Chesson HW, Collins D, Koski K. Formulas for estimating the costs averted by sexually transmitted infection (STI) prevention programs in the United States. Cost Eff Resour Alloc. 2008;6:10.PubMedCrossRefGoogle Scholar
  71. 71.
    Karlsson G, Johannesson M. The decision rules of cost-effectiveness analysis. Pharmacoeconomics. 1996;9:113–20.PubMedCrossRefGoogle Scholar
  72. 72.
    Drummond M, Torrance G, Mason J. Cost-effectiveness league tables: more harm than good? Soc Sci Med. 1993;37:33–40.PubMedCrossRefGoogle Scholar
  73. 73.
    Mason J, Drummond M, Torrance G. Some guidelines on the use of cost effectiveness league tables. BMJ. 1993;306:570–2.PubMedCrossRefGoogle Scholar
  74. 74.
    Neumann PJ, Jacobson PD, Palmer JA. Measuring the value of public health systems: the disconnect between health economists and public health practitioners. Am J Public Health. 2008;98:2173–80.PubMedCrossRefGoogle Scholar
  75. 75.
    Valdiserri RO, Robinson C, Lin LS, West GR, Holtgrave DR. Determining allocations for HIV-prevention interventions: assessing a change in federal funding policy. AIDS Public Policy J. 1997;12:138–48.PubMedGoogle Scholar
  76. 76.
    Holtgrave DR, Curran JW. What works, and what remains to be done, in HIV prevention in the United States. Annu Rev Public Health. 2006;27:261–75.PubMedCrossRefGoogle Scholar
  77. 77.
    Holtgrave DR. Measuring the value of public health systems. Am J Public Health. 2009;99:775–6.PubMedCrossRefGoogle Scholar
  78. 78.
    Weinstein B, Melcchreit RL. Economic evaluation and HIV prevention decision making. In: Holtgrave DR, editor. Handbook of economic evaluation of HIV prevention programs. New York: Plenum; 1998. p. 153–62.Google Scholar
  79. 79.
    Lasry A, Richter A, Lutscher F. Recommendations for increasing the use of HIV/AIDS resource allocation models. BMC Public Health. 2009;9 Suppl 1:S8.Google Scholar
  80. 80.
    Kahn JG, Brandeau ML, Dunn-Mortimer J. OR modeling and AIDS policy: from theory to practice. Interfaces. 1998;28:3–22.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Harrell W. Chesson
    • 1
    Email author
  • Steven D. Pinkerton
    • 2
  • David R. Holtgrave
    • 3
  1. 1.Division of STD PreventionCenters for Disease Control and PreventionAtlantaUSA
  2. 2.Department of Psychiatry and Behavioral Medicine, Medical College of WisconsinCenter for AIDS Intervention Research (CAIR)MilwaukeeUSA
  3. 3.Bloomberg School of Public HealthJohns Hopkins UniversityBaltimoreUSA

Personalised recommendations